Trial reportFrontiers in cellular and infection microbiology2026
Clinical efficacy of Radix Arnebiae oil in patients undergoing incision and drainage of perianal abscess and its effects on pyroptosis.
Trial report in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to assess the clinical efficacy of Radix Arnebiae oil (RAO) in patients undergoing incision and drainage of perianal abscess and to investigate its effects on pyroptosis-related factors, thereby providing evidence to support its clinical application and offering insights into its potential mechanism of action. Methods: Ninety patients were randomly assigned to three groups (n = 30 per group) using a random number table: the RAO group, the Moist Exposed Burn Ointment (MEBO) group, and the petrolatum group. Beginning on postoperative day (POD) 1, the assigned topical agent was applied to the wound in each group and continued until complete wound healing. Pain and wound exudate scores were assessed on PODs 3, 7, and 14. In addition, wound healing rates and healing duration were recorded. Protein expression levels of caspase-1, interleukin (IL)-1β, and IL-18 were assessed using enzyme-linked immunosorbent assay (ELISA) and immunohistochemical (IHC) staining. Results: Treatment with RAO significantly alleviated postoperative pain and reduced wound exudation following incision and drainage of perianal abscess. On POD 14, the corresponding scores in the RAO group were significantly lower than those in the MEBO and petrolatum groups (p < 0.05). The RAO group demonstrated a higher wound healing rate and a significantly shorter healing duration than the MEBO and petrolatum groups (both p < 0.05). The overall clinical efficacy was significantly greater in the RAO group than in the other two treatment groups (p < 0.05). ELISA findings on POD 14 showed significantly lower protein expression levels of caspase-1, IL-1β, and IL-18 in the RAO group than in the petrolatum and MEBO groups, with statistically significant differences (all p < 0.05). Consistent with these findings, IHC staining demonstrated reduced expression of these proteins in the RAO group compared with the MEBO and petrolatum groups. Conclusion: RAO alleviates postoperative pain, reduces wound exudation, and promotes wound healing in patients undergoing incision and drainage of perianal abscess. Its mechanism of action may be associated with the regulation of pyroptosis-related mediators, including caspase-1, IL-1β, and IL-18.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.